Abeona Therapeutics Strengthens Financial Position with $155 Million Sale of PRV

CLEVELAND, July 02, 2025 (GLOBE NEWSWIRE) – Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the successful closing of the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $155 million on June 27, 2025.

This significant transaction, combined with existing reserves, boosts Abeona’s unaudited cash, cash equivalents, restricted cash, and short-term investments to approximately $225 million as of June 30, 2025.

“We have reached another key milestone: the successful sale of our PRV has closed,” stated Joe Vazzano, Chief Financial Officer of Abeona. “The PRV proceeds, combined with our existing cash, provides Abeona with robust financial flexibility, ensuring over two years of operating capital for sustained growth without the need for further capital infusion and prior to accounting for ZEVASKYN sales. We anticipate the first ZEVASKYN patient treatment in Q3 2025, with profitability projected for early 2026.”

About the PRV and ZEVASKY: Abeona was awarded the PRV by the U.S. Food and Drug Administration (FDA) in April 2025, following the FDA’s approval of ZEVASKYN™ (prademagene zamikeracel). ZEVASKYN is notably the first and only U.S. approved autologous cell-based gene therapy for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB).